About the workshop

DID YOU MISS OUR EDUCATIONAL SYMPOSIUM AT EUROMEDLAB 2019?

Add specialty to your routine: Reviewing a new Anti-Mullerian hormone assay and the first complete panel for fully automated biomarker testing in Alzheimer's disease

EuroMedLab Educational Symposium - Fujirebio
(Re)view the entire workshop and browse the slides in our Documentation Package!

 

Speakers:

  • Sjoerd van den Berg - Head, Diagnostic Endocrinology Laboratory, Erasmus MC, Department of Clinical Chemistry (AKC), Rotterdam, The Netherlands
     
  • Daniel Alcolea - Adjunto del Servicio de Neurología, Sant Pau Memory Unit. Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 
Detailed Program:

  • 16.00-16.30
    Detailed insight into the low range sensitivity and performance of Lumipulse® G AMH
    Sjoerd van den Berg
     
  • 16.30 – 17.00
    A complete CSF biomarker profile for Alzheimer’s disease in the era of automation and standardization
    Daniel Alcolea

 

Download documentation package below

The speakers

Sjoerd van den Berg

Sjoerd van den Berg

Sjoerd obtained his PhD in endocrinology at the Leiden University Medical Center, Leiden, The Netherlands.  Afterwards he continued as a postdoc at the LUMC in the same research field. Subsequently he was trained as a specialist in laboratory medicine, with special interest in endocrinology. Currently, he heads the diagnostic laboratory for endocrinology of the Erasmus University Medical Center, Rotterdam, The Netherlands. To date, he (co)authored over 50 research papers which have collectively been cited ~2500 times, on various endocrinological topics. Currently, his research interests focus on state-of-the art diagnostic assays for reproductive, thyroid and adrenal abnormalities.

Daniel Alcolea

Daniel Alcolea

The main interest in his research career has been the study of cerebrospinal fluid Alzheimer's disease biomarkers. This was the focus of his Doctoral Thesis, awarded as best thesis in neuroscience by the Spanish Society of Neurology. His studies have significantly contributed to the field of biomarkers and are reflected in more than 100 communications in national and international congresses, and over 50 publications in high impact journals (>70% in first quartile) that have obtained more than 1000 citations. As a Neurologist of the Sant Pau Memory Unit during the last 10 years, he has gained clinical expertise in the diagnosis and treatment of patients with memory problems. He also had the opportunity to combine research and assistance with academic responsibilities as a Clinical Associate in the faculty of Medicine at the Autonomous University of Barcelona, supervisor of training residents in Neurology, director of a masters degree thesis and collaborator as a speaker in more than 20 meetings and congresses both scientific/academic and educational.

Symposium summary

Fujirebio is a leader in providing in vitro diagnostics testing solutions, and a pioneer in automated chemiluminescence methods. This educational workshop will review newly developed assays in two different areas, namely the AMH (anti-Müllerian hormone) test within the fertility panel and a complete biomarker panel for Alzheimer’s disease biomarkers on the LUMIPULSE® G platform.

The Lumipulse G AMH assay was launched by Fujirebio Europe in the first half of 2019.  The assay is based on a two-step sandwich immunoassay concept. The workshop will give detailed insight into the low range performance, which may be particularly interesting in prediction of ovarian reserve, time to menopause and may aid in the diagnosis and follow up of ovarian cancer.

Under the INNOTEST® brand name, Fujirebio pioneered in the field of neurodegenerative disease testing by commercializing the first in vitro diagnostic biomarkers for Alzheimer’s disease. The steadily growing acceptance of the clinical value of Alzheimer biomarkers, coupled with the expectation of new therapies, sets the stage for the fully automated processing of cerebrospinal fluid (CSF) samples. The Lumipulse G pTau 181 and β-Amyloid1-40 assays, launched in November 2018, are the latest additions to Fujirebio’s fully automated Alzheimer product line and complement the previously launched Lumipulse G Total Tau and β-Amyloid1-42 assays. These assays are intended to measure β-Amyloid1-42, β-Amyloid1-40, Total Tau and pTau 181 in CSF. Altogether, these four CSF markers support the diagnosis of Alzheimer’s disease, with the β-Amyloid1-42 / β-Amyloid1-40 ratio additionally being able to reduce the effect of inappropriate pre-analytics. The workshop will review the performance of Fujirebio’s Alzheimer biomarker panel available on the LUMIPULSE G automated analyzers.

Sign up now!

Sign up in the form below to access the full documentation package right away and to get access to material from the workshop, including the recorded videos.

Download documentation

Fields indicated with a star are mandatory

The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.